Browse the corpus

REFERENCES Hamnvik OP, Larsen PR, and Marqusee E, “Thyroid Dysfunction From Antineoplastic Agents,” J Natl Cancer Inst , 2011, 103(21):1572-87. [PubMed 22010182 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Pithavala YK, Chen Y, Toh M, et al, “Evaluation of the Effect of Food on the Pharmacokinetics of Axitinib in Healthy Volunteers,” Cancer Chemother Pharmacol , 2012, 70(1):103-12. [PubMed 22644797 ] Rini BI, Escudier B, Tomczak P, et al, “Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial,” Lancet , 2011, 378(9807):1931-9. [PubMed 22056247 ] Rini BI, Escudier BJ, Michaelson MD, et al, “Phase III AXIS Trial for Second-Line Metastatic Renal Cell Carcinoma (Mrcc): Effect of Prior First-Line Treatment Duration and Axitinib Dose Titration on Axitinib Efficacy,” J Clin Oncol , 2012, 30(5):354 [abstract 354 from 2012 ASCO Genitourinary Cancers Symposium]. Rini BI, Wilding G, Hudes G, et al, “Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma,” J Clin Oncol , 2009, 27(27):4462-8. [PubMed 19652060 ] Rixe O, Bukowski RM, Michaelson MD, et al, “Axitinib Treatment in Patients With Cytokine-Refractory Metastatic Renal-Cell Cancer: A Phase II Study,” Lancet Oncol , 2007, 8(11):975-84. [PubMed 17959415 ] Rugo HS, Herbst RS, Liu G, et al, “Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results,” J Clin Oncol , 2005, 23(24):5474-83. [PubMed 16027439 ] Topic 17141 Version 11.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1104-58.240.98.179-704953041C-S244013.14]